

Daniel Weintraub

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7484166/daniel-weintraub-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

349
papers

26,189
citations

81
h-index

155
g-index

377
ext. papers

31,831
ext. citations

6.4
avg, IF

6.94
L-index

#	Paper	IF	Citations
349	The neuropsychiatry of Parkinson's disease: advances and challenges.. <i>Lancet Neurology, The</i> , 2022 , 21, 89-102	24.1	10
348	Validation of the Japanese Version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS).. <i>Parkinsons Disease</i> , 2022 , 2022, 1503167	2.6	1
347	Level I PD-MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia.. <i>Movement Disorders Clinical Practice</i> , 2022 , 9, 479-483	2.2	0
346	Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias. <i>Neurology</i> , 2021 , 96, e1855-e1864	6.5	11
345	A Model to Assess the Outcomes Associated With Dementia With Lewy Bodies. <i>Alzheimer Disease and Associated Disorders</i> , 2021 , 35, 68-74	2.5	1
344	Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration. <i>Neurology: Clinical Practice</i> , 2021 , 11, 105-116	1.7	2
343	Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson's disease. <i>Brain and Behavior</i> , 2021 , 11, e02086	3.4	1
342	Innovating Parkinson's Care: A Randomized Controlled Trial of Telemedicine Depression Treatment. <i>Movement Disorders</i> , 2021 , 36, 2549-2558	7	6
341	Parkinson's Disease Subtypes: Critical Appraisal and Recommendations. <i>Journal of Parkinsons Disease</i> , 2021 , 11, 395-404	5.3	7
340	Whole Clinic Research Enrollment in Parkinson's Disease: The Molecular Integration in Neurological Diagnosis (MIND) Study. <i>Journal of Parkinsons Disease</i> , 2021 , 11, 757-765	5.3	1
339	Psychometric Properties of the Clinical Dementia Rating Scale Sum of Boxes in Parkinson's Disease. <i>Journal of Parkinsons Disease</i> , 2021 , 11, 737-745	5.3	1
338	Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 1972-1978	7	1
337	Prodromal Dementia With Lewy Bodies: Evolution of Symptoms and Predictors of Dementia Onset. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2021 , 8919887211023586	3.8	3
336	Movement in Aesthetic Experiences: What We Can Learn from Parkinson Disease. <i>Journal of Cognitive Neuroscience</i> , 2021 , 33, 1329-1342	3.1	0
335	Low continuation of antipsychotic therapy in Parkinson disease - intolerance, ineffectiveness, or inertia?. <i>BMC Neurology</i> , 2021 , 21, 240	3.1	2
334	Trial of Pimavanserin in Dementia-Related Psychosis. <i>New England Journal of Medicine</i> , 2021 , 385, 309-319	59.2	18
333	Parkinson disease-associated cognitive impairment. <i>Nature Reviews Disease Primers</i> , 2021 , 7, 47	51.1	55

332	Annual Prevalence of Use of Potentially Inappropriate Medications for Treatment of Affective Disorders in Parkinson's Disease. <i>American Journal of Geriatric Psychiatry</i> , 2021 , 29, 35-47	6.5	0
331	Differences in the Presentation and Progression of Parkinson's Disease by Sex. <i>Movement Disorders</i> , 2021 , 36, 106-117	7	16
330	Prevalence of Non-Motor Symptoms and Non-Motor Fluctuations in Parkinson's Disease Using the MDS-NMS. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 231-239	2.2	8
329	The Non-Motor Symptoms Scale in Parkinson's disease: Validation and use. <i>Acta Neurologica Scandinavica</i> , 2021 , 143, 3-12	3.8	16
328	International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 2583-2594	7	9
327	Constipation is Associated with Development of Cognitive Impairment in de novo Parkinson's Disease: A Longitudinal Analysis of Two International Cohorts. <i>Journal of Parkinsons Disease</i> , 2021 , 11, 1209-1219	5.3	8
326	Assessment of Affective-Behavioral States in Parkinson's Disease Patients: Towards a New Screening Tool. <i>Journal of Parkinsons Disease</i> , 2021 , 11, 1417-1430	5.3	
325	Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease. <i>Movement Disorders</i> , 2021 ,	7	3
324	Predictors of short-term impulsive and compulsive behaviour after subthalamic stimulation in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 , 92, 1313-1318	5.5	3
323	Antimuscarinic Anticholinergic Medications in Parkinson Disease: To Prescribe or Deprescribe?. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 1181-1188	2.2	1
322	Dopamine transporter imaging predicts clinically-defined α -synucleinopathy in REM sleep behavior disorder. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 201-212	5.3	6
321	Identifying Parkinson's disease subtypes with motor and non-motor symptoms via model-based multi-partition clustering. <i>Scientific Reports</i> , 2021 , 11, 23645	4.9	2
320	Does a Positive Amyloid Scan Always Mean Alzheimer Disease? 2020 , 99-102		
319	I Don't Know When to Stop 2020 , 149-152		
318	Caring for the Caregiver 2020 , 155-157		
317	Cognitive Decline Is Only Part of the Story 2020 , 4-6		
316	Not Recognizing the Impostor 2020 , 64-66		
315	Cognitive Impairment as an Unexpected Guest 2020 , 75-77		

314 What Is Not How I Feel? *2020*, 96-98

313	Is Rapid Eye Movement Sleep Behavior Disorder a Risk Factor for Impulse Control Disorder in Parkinson Disease?. <i>Annals of Neurology</i> , 2020 , 88, 759-770	9.4	6
312	Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease. <i>Annals of Neurology</i> , 2020 , 88, 574-587	9.4	16
311	Management of psychiatric disorders in Parkinson's disease : Neurotherapeutics - Movement Disorders Therapeutics. <i>Neurotherapeutics</i> , 2020 , 17, 1511-1524	6.4	9
310	Subjective Cognitive Complaint in Parkinson's Disease Patients With Normal Cognition: Canary in the Coal Mine?. <i>Movement Disorders</i> , 2020 , 35, 1618-1625	7	12
309	Factor Analysis and Clustering of the Movement Disorder Society-Non-Motor Rating Scale. <i>Movement Disorders</i> , 2020 , 35, 969-975	7	5
308	Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study. <i>Movement Disorders</i> , 2020 , 35, 833-844	7	18
307	Measurement properties from the Brazilian Portuguese version of the QUIP-RS. <i>Npj Parkinsons Disease</i> , 2020 , 6, 6	9.7	4
306	Impulse control and related behaviors in Parkinson's disease with dementia. <i>European Journal of Neurology</i> , 2020 , 27, 944-950	6	10
305	Frequency of and risk factors for potentially inappropriate medication use in Parkinson's disease. <i>Age and Ageing</i> , 2020 , 49, 786-792	3	3
304	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. <i>Lancet Neurology</i> , 2020 , 19, 71-80	24.1	37
303	Drug and Disease Effects in Parkinson's Psychosis: Revisiting the Role of Dopamine. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 32-36	2.2	8
302	The movement disorder society nonmotor rating scale: Initial validation study. <i>Movement Disorders</i> , 2020 , 35, 116-133	7	33
301	Multimodal in vivo and postmortem assessments of tau in Lewy body disorders. <i>Neurobiology of Aging</i> , 2020 , 96, 137-147	5.6	4
300	0075 Neural Correlates of Cognitive Fatigue in Parkinson Disease. <i>Sleep</i> , 2020 , 43, A30-A30	1.1	
299	Direct Medical Costs of Dementia With Lewy Bodies by Disease Complexity. <i>Journal of the American Medical Directors Association</i> , 2020 , 21, 1696-1704.e5	5.9	5
298	Clinical Follow-up of Parkinson's Disease With Newly Prescribed Quetiapine. <i>Movement Disorders</i> , 2020 , 35, 1690-1692	7	
297	ADNC-RS, a clinical-genetic risk score, predicts Alzheimer's pathology in autopsy-confirmed Parkinson's disease and Dementia with Lewy bodies. <i>Acta Neuropathologica</i> , 2020 , 140, 449-461	14.3	3

296	Hallucinations and Development of Dementia in Parkinson's Disease. <i>Journal of Parkinsons Disease</i> , 2020 , 10, 1643-1648	5.3	1
295	Tau pathology associates with in vivo cortical thinning in Lewy body disorders. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 2342-2355	5.3	8
294	Hippocampal subfield pathologic burden in Lewy body diseases vs. Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2020 , 46, 707-721	5.2	7
293	Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression. <i>Movement Disorders</i> , 2020 , 35, 1999-2008	7	32
292	New evidence on the management of Lewy body dementia. <i>Lancet Neurology, The</i> , 2020 , 19, 157-169	24.1	70
291	Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 449-461	5.3	18
290	Genetic risk of Parkinson disease and progression:: An analysis of 13 longitudinal cohorts. <i>Neurology: Genetics</i> , 2019 , 5, e348	3.8	57
289	Non-motor outcomes depend on location of neurostimulation in Parkinson's disease. <i>Brain</i> , 2019 , 142, 3592-3604	11.2	54
288	Pilot Study of the International Parkinson and Movement Disorder Society-sponsored Non-motor Rating Scale (MDS-NMS). <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 227-234	2.2	17
287	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). <i>Parkinsonism and Related Disorders</i> , 2019 , 62, 201-209	3.6	9
286	Lack of independent mood-enhancing effect for dopaminergic medications in early Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2019 , 402, 81-85	3.2	5
285	Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2019 , 34, 791-798	7	25
284	Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression. <i>Npj Parkinsons Disease</i> , 2019 , 5, 7	9.7	24
283	The Neuropsychiatry of Parkinson Disease: A Perfect Storm. <i>American Journal of Geriatric Psychiatry</i> , 2019 , 27, 998-1018	6.5	44
282	Impulse control disorders in Parkinson's disease: A 20-year odyssey. <i>Movement Disorders</i> , 2019 , 34, 447-452	7.5	8
281	French validation of the questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS). <i>Parkinsonism and Related Disorders</i> , 2019 , 63, 117-123	3.6	6
280	Integration and Extension of Specialty Mental Healthcare Services to Community Practice in Parkinson Disease. <i>American Journal of Geriatric Psychiatry</i> , 2019 , 27, 712-719	6.5	9
279	TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia. <i>Annals of Neurology</i> , 2019 , 85, 801-811	9.4	23

278	Cognitive Functional Abilities in Parkinson's Disease: Agreement Between Patients and Informants. <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 440-445	2.2	9
277	Longitudinal analyses of cerebrospinal fluid α -Synuclein in prodromal and early Parkinson's disease. <i>Movement Disorders</i> , 2019 , 34, 1354-1364	7	48
276	Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. <i>Movement Disorders</i> , 2019 , 34, 1839-1850	7	69
275	Characterization of Parkinson's disease using blood-based biomarkers: A multicohort proteomic analysis. <i>PLoS Medicine</i> , 2019 , 16, e1002931	11.6	17
274	From action to abstraction: The sensorimotor grounding of metaphor in Parkinson's disease. <i>Cortex</i> , 2019 , 121, 362-384	3.8	10
273	Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies. <i>Parkinsonism and Related Disorders</i> , 2019 , 69, 119-124	3.6	7
272	Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's disease. <i>Npj Parkinsons Disease</i> , 2019 , 5, 30	9.7	20
271	Smaller subcortical volume in Parkinson patients with rapid eye movement sleep behavior disorder. <i>Brain Imaging and Behavior</i> , 2019 , 13, 1352-1360	4.1	10
270	Modifiable vascular risk factors, white matter disease and cognition in early Parkinson's disease. <i>European Journal of Neurology</i> , 2019 , 26, 246-e18	6	26
269	Impulse Control Disorders in Parkinson's Disease. <i>American Journal of Psychiatry</i> , 2019 , 176, 5-11	11.9	15
268	Pharmacological treatment of apathy in Lewy body disorders: A systematic review. <i>Parkinsonism and Related Disorders</i> , 2019 , 60, 14-24	3.6	11
267	Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. <i>Movement Disorders</i> , 2019 , 34, 180-198	7	357
266	Risk of Parkinson's disease dementia related to level I MDS PD-MCI. <i>Movement Disorders</i> , 2019 , 34, 430-435	7	21
265	Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology. <i>Alzheimer's and Dementia</i> , 2019 , 15, 55-64	1.2	50
264	Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. <i>JAMA Neurology</i> , 2019 , 76, 318-325	17.2	94
263	Patterns of Dementia Treatment and Frank Prescribing Errors in Older Adults With Parkinson Disease. <i>JAMA Neurology</i> , 2019 , 76, 41-49	17.2	26
262	Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders. <i>Annals of Neurology</i> , 2019 , 85, 259-271	9.4	41
261	CSF tau and β amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. <i>Neurology</i> , 2018 , 90, e1038-e1046	6.5	43

260	Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect. <i>Movement Disorders</i> , 2018 , 33, 499-500	7	0
259	Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort. <i>Movement Disorders</i> , 2018 , 33, 771-782	7	73
258	Quantitative assessment of finger tapping characteristics in mild cognitive impairment, Alzheimer's disease, and Parkinson's disease. <i>Journal of Neurology</i> , 2018 , 265, 1365-1375	5.5	39
257	Selection of Normative Group Affects Rates of Mild Cognitive Impairment in Parkinson's Disease. <i>Movement Disorders</i> , 2018 , 33, 839-843	7	11
256	At a crossroads: Revisiting mild cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 501-502	7	0
255	Optimizing olfactory testing for the diagnosis of Parkinson's disease: item analysis of the university of Pennsylvania smell identification test. <i>Npj Parkinsons Disease</i> , 2018 , 4, 2	9.7	32
254	Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. <i>Acta Neuropathologica</i> , 2018 , 136, 363-376	14.3	83
253	Initial cognitive changes in Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 511-519	7	33
252	Cerebrospinal fluid β -synuclein contributes to the differential diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1052-1062	1.2	27
251	Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 78-88	5.5	49
250	Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2018 , 33, 450-457	2.5	15
249	Cognition among individuals along a spectrum of increased risk for Parkinson's disease. <i>PLoS ONE</i> , 2018 , 13, e0201964	3.7	21
248	Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. <i>Brain</i> , 2018 , 141, 2181-2193	11.2	245
247	Prevalence of Impulsive-Compulsive Symptoms in Elderly Parkinson's Disease Patients: A Case-Control Study. <i>Journal of Clinical Psychiatry</i> , 2018 , 79,	4.6	6
246	APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 289-297	7	24
245	Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2018 , 33, 208-218	7	80
244	The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 1460-1477	5.3	142
243	Validation of a performance-based assessment of cognitive functional ability in Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 1760-1768	7	10

242	Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. <i>Movement Disorders</i> , 2018 , 33, 1769-1776	7	18
241	Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests. <i>Movement Disorders</i> , 2018 , 33, 1750-1759	7	22
240	The Case for Antipsychotics in Dementia with Lewy Bodies. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 32-35	2.2	12
239	The psychosis spectrum in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017 , 13, 81-95	15	165
238	The bidirectional longitudinal relationship between insomnia, depression and anxiety in patients with early-stage, medication-naïve Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017 , 39, 31-36	3.6	21
237	Antipsychotic Use and Physical Morbidity in Parkinson Disease. <i>American Journal of Geriatric Psychiatry</i> , 2017 , 25, 697-705	6.5	24
236	The depressed brain in Parkinson's disease: Implications for an inflammatory biomarker. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 3004-3005	11.5	5
235	Cognitive decline in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017 , 13, 217-231	15	458
234	Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease. <i>Neurobiology of Aging</i> , 2017 , 56, 211.e1-211.e7	5.6	24
233	Impulse Control Disorders and Related Complications of Parkinson's Disease Therapy. <i>Seminars in Neurology</i> , 2017 , 37, 186-192	3.2	18
232	Longitudinal decline in speech production in Parkinson's disease spectrum disorders. <i>Brain and Language</i> , 2017 , 171, 42-51	2.9	25
231	Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. <i>Neurology</i> , 2017 , 89, 88-100	6.5	1691
230	Cognitive decline before diagnosis of Parkinson's disease - Authors' reply. <i>Lancet Neurology</i> , 2017 , 16, 262	24.1	2
229	Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease. <i>Neuropathology and Applied Neurobiology</i> , 2017 , 43, 604-620	5.2	38
228	Neuropsychological Subgroups in Non-Demented Parkinson's Disease: A Latent Class Analysis. <i>Journal of Parkinsons Disease</i> , 2017 , 7, 385-395	5.3	15
227	Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort. <i>Journal of Alzheimer's Disease</i> , 2017 , 57, 787-795	4.3	54
226	Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 325-331	5.5	51
225	Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. <i>Lancet Neurology</i> , 2017 , 16, 55-65	24.1	273

224	Cognition and the course of prodromal Parkinson's disease. <i>Movement Disorders</i> , 2017 , 32, 1640-1645	7	29
223	Regional brain amyloid- β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. <i>PLoS ONE</i> , 2017 , 12, e0177924	3.7	25
222	Parkinson's Disease Impulsive-Compulsive Disorders Questionnaire [Current Short (QUIP-CS)] Translation and validation of content of Portuguese Version. <i>Jornal Brasileiro De Psiquiatria</i> , 2017 , 66, 111-115	0.5	3
221	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. <i>Movement Disorders</i> , 2017 , 32, 1264-1310	7	375
220	Statins and Cognition in Parkinson's Disease. <i>Journal of Parkinsons Disease</i> , 2017 , 7, 661-667	5.3	10
219	Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype. <i>Annals of Clinical and Translational Neurology</i> , 2017 , 4, 15-25	5.3	26
218	Predictors of anxiety in early-stage Parkinson's disease - Results from the first two years of a prospective cohort study. <i>Parkinsonism and Related Disorders</i> , 2017 , 43, 49-55	3.6	18
217	Impulse Control and Related Disorders in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017 , 133, 679-717	4.4	136
216	Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study. <i>Lancet Neurology</i> , 2017 , 16, 66-75	24.1	201
215	A Consensus Set of Outcomes for Parkinson's Disease from the International Consortium for Health Outcomes Measurement. <i>Journal of Parkinsons Disease</i> , 2017 , 7, 533-543	5.3	31
214	Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 89	9	85
213	Narrative Organization Deficit in Lewy Body Disorders Is Related to Alzheimer Pathology. <i>Frontiers in Neuroscience</i> , 2017 , 11, 53	5.1	2
212	Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. <i>PLoS ONE</i> , 2017 , 12, e0175674	3.7	84
211	CSF β Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease. <i>Journal of Molecular Neuroscience</i> , 2016 , 58, 88-92	3.3	63
210	Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2016 , 29, 59-64	3.8	6
209	Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. <i>JAMA Neurology</i> , 2016 , 73, 1217-1224	17.2	120
208	Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. <i>Journal of Alzheimer's Disease</i> , 2016 , 54, 287-95	4.3	50
207	Fatigue in Parkinson's disease: report from a multidisciplinary symposium. <i>Npj Parkinsons Disease</i> , 2016 , 2,	9.7	45

206	Research consent capacity varies with executive function and memory in Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 414-7	7	9
205	Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease. <i>Journal of Psychiatric Research</i> , 2016 , 74, 17-21	5.2	33
204	Amyloid-Beta Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 367-375	2.2	22
203	Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 270-9	7	44
202	Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial. <i>Movement Disorders</i> , 2016 , 31, 709-14	7	36
201	Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. <i>American Journal of Psychiatry</i> , 2016 , 173, 465-72	11.9	60
200	Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease. <i>JAMA Neurology</i> , 2016 , 73, 535-41	17.2	101
199	GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 95-102	7	113
198	CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. <i>Acta Neuropathologica</i> , 2016 , 131, 935-49	14.3	138
197	MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study. <i>Journal of Neural Transmission</i> , 2016 , 123, 431-8	4.3	76
196	Olfactory impairment predicts cognitive decline in early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016 , 25, 45-51	3.6	69
195	A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2016 , 43, 99-109	2.7	7
194	Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 864-70	5.5	76
193	Decision-Making Deficits Associated with Amyloidosis in Lewy Body Disorders. <i>Frontiers in Human Neuroscience</i> , 2016 , 10, 693	3.3	1
192	An Alzheimer's Disease-Derived Biomarker Signature Identifies Parkinson's Disease Patients with Dementia. <i>PLoS ONE</i> , 2016 , 11, e0147319	3.7	18
191	Parkinson's disease-related fatigue: A case definition and recommendations for clinical research. <i>Movement Disorders</i> , 2016 , 31, 625-31	7	63
190	Memantine and Cognition in Parkinson's Disease Dementia/Dementia With Lewy Bodies: A Meta-Analysis. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 161-167	2.2	9
189	R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 784-92	3.8	41

188	A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. <i>European Journal of Neurology</i> , 2016 , 23, 1255-61	6	58
187	Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2016 , 3, 346-55	5.3	26
186	Development and Validation of the Parkinson's Disease Medication Beliefs Scale (PD-Rx). <i>Journal of Parkinsons Disease</i> , 2016 , 6, 383-92	5.3	2
185	Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1106-11	5.5	70
184	Hospital care for mental health and substance abuse conditions in Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 1810-1819	7	8
183	Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behavior disorder. <i>Parkinsonism and Related Disorders</i> , 2016 , 27, 102-6	3.6	70
182	The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016 , 25, 21-6	3.6	27
181	Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study. <i>American Journal of Psychiatry</i> , 2016 , 173, 473-80	11.9	48
180	Principal components analysis of agitation outcomes in Alzheimer's disease. <i>Journal of Psychiatric Research</i> , 2016 , 79, 4-7	5.2	3
179	High patient satisfaction with telehealth in Parkinson disease: A randomized controlled study. <i>Neurology: Clinical Practice</i> , 2016 , 6, 241-251	1.7	55
178	Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis. <i>European Journal of Neurology</i> , 2016 , 23, 1556-65	6	42
177	Arguing against the proposed definition changes of PD. <i>Movement Disorders</i> , 2016 , 31, 1619-1622	7	43
176	The Danger of Not Treating Parkinson Disease Psychosis-Reply. <i>JAMA Neurology</i> , 2016 , 73, 1156-7	17.2	2
175	Development and initial testing of the Penn Parkinson's Daily Activities Questionnaire. <i>Movement Disorders</i> , 2016 , 31, 126-34	7	16
174	Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings. <i>Movement Disorders</i> , 2016 , 31, 86-94	7	66
173	Is the Parkinson Anxiety Scale comparable across raters?. <i>Movement Disorders</i> , 2015 , 30, 545-51	7	7
172	Patterns of cortical thickness associated with impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 688-95	7	63
171	Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability. <i>JAMA Neurology</i> , 2015 , 72, 88-95	17.2	73

170	Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 629-34	3.6	118
169	Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 919-27	7	179
168	Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. <i>Lancet Neurology, The</i> , 2015 , 14, 1002-9	24.1	141
167	Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. <i>Neurology</i> , 2015 , 84, 1386-7	6.5	8
166	Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2015 , 23, 1127-33	6.5	20
165	Longitudinal study of normal cognition in Parkinson disease. <i>Neurology</i> , 2015 , 85, 1276-82	6.5	144
164	Caregiver report of apathy predicts dementia in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 992-5	3.6	24
163	Lower plasma apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype. <i>Movement Disorders</i> , 2015 , 30, 805-12	7	29
162	Clinical spectrum of impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 1217-7	7	203
161	Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial. <i>International Psychogeriatrics</i> , 2015 , 27, 2059-67	3.4	17
160	Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease. <i>Journal of Parkinsons Disease</i> , 2015 , 5, 783-92	5.3	31
159	Olfactory dysfunction in Parkinson's disease: Positive effect of cigarette smoking. <i>Movement Disorders</i> , 2015 , 30, 859-62	7	25
158	Advances in the treatment of cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 1471-89	7	50
157	Scales to Assess Clinical Features of Progressive Supranuclear Palsy: MDS Task Force Report. <i>Movement Disorders Clinical Practice</i> , 2015 , 2, 127-134	2.2	14
156	Reply to letter to the editor 'Independent application of MoCA/MMSE conversion' by Armstrong et al. <i>Movement Disorders</i> , 2015 , 30, 1711	7	
155	Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study. <i>Movement Disorders</i> , 2015 , 30, 912-8	7	76
154	Treatment changes among older patients with dementia treated with antipsychotics. <i>International Journal of Geriatric Psychiatry</i> , 2015 , 30, 1238-49	3.9	2
153	Cognitive profile of LRRK2-related Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 728-33	7	42

152	Psychiatric issues in cognitive impairment. <i>Movement Disorders</i> , 2014 , 29, 651-62	7	37
151	Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group. <i>Movement Disorders</i> , 2014 , 29, 857-67	7	148
150	Anxiety has specific syndromal profiles in Parkinson disease: a data-driven approach. <i>American Journal of Geriatric Psychiatry</i> , 2014 , 22, 1410-7	6.5	27
149	Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease (QUIP) and the QUIP-rating scale in a German speaking sample. <i>Journal of Neurology</i> , 2014 , 261, 936-42	5.5	32
148	The Parkinson Anxiety Scale (PAS): development and validation of a new anxiety scale. <i>Movement Disorders</i> , 2014 , 29, 1035-43	7	117
147	Impulsive and compulsive behaviors among Danish patients with Parkinson's disease: prevalence, depression, and personality. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 22-6	3.6	70
146	Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer's Disease Study 2. <i>American Journal of Geriatric Psychiatry</i> , 2014 , 22, 14-24	6.5	5
145	Initial cognitive decline is associated with cortical thinning in early Parkinson disease. <i>Neurology</i> , 2014 , 82, 2017-25	6.5	122
144	Impulse control and related disorders in Mexican Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 907-10	3.6	32
143	Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtable. <i>Journal of Parkinsons Disease</i> , 2014 , 4, 585-9	5.3	14
142	Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial. <i>PLoS ONE</i> , 2014 , 9, e98426	3.7	40
141	Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 682-91	27.4	337
140	Benefit finding and relationship quality in Parkinson's disease: a pilot dyadic analysis of husbands and wives. <i>Journal of Family Psychology</i> , 2014 , 28, 728-34	2.7	20
139	People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance. <i>Movement Disorders</i> , 2014 , 29, 1258-64	7	50
138	Introduction: the importance of cognition in movement disorders. <i>Movement Disorders</i> , 2014 , 29, 581-3	7	4
137	Cognition in movement disorders: where can we hope to be in ten years?. <i>Movement Disorders</i> , 2014 , 29, 704-11	7	13
136	Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. <i>Neurology</i> , 2014 , 83, 826-33	6.5	59
135	Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease. <i>Movement Disorders</i> , 2014 , 29, 1809-15	7	62

134	APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. <i>JAMA Neurology</i> , 2014 , 71, 1405-12	17.2	135
133	Course of psychiatric symptoms and global cognition in early Parkinson disease. <i>Neurology</i> , 2014 , 83, 1096-103	6.5	82
132	Task force report: scales for screening and evaluating tremor: critique and recommendations. <i>Movement Disorders</i> , 2013 , 28, 1793-800	7	96
131	Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson's disease: results from a randomised, controlled trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, 1113-8	5.5	119
130	APOE ϵ increases risk for dementia in pure synucleinopathies. <i>JAMA Neurology</i> , 2013 , 70, 223-8	17.2	243
129	Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa?. <i>Movement Disorders</i> , 2013 , 28, 1915-9	7	26
128	Neuropsychologic assessment in collaborative Parkinson's disease research: a proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson's Disease Research at the University of Pennsylvania and the University of Washington. <i>Alzheimer's and Dementia</i> , 2013 , 9, 609-14	1.2	22
127	Impulse control and related disorders in Parkinson's disease. <i>Neurodegenerative Diseases</i> , 2013 , 11, 63-71	3.3	68
126	Designing a new scale to measure anxiety symptoms in Parkinson's disease: item selection based on canonical correlation analysis. <i>European Journal of Neurology</i> , 2013 , 20, 1198-203	6	14
125	Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. <i>Neurology</i> , 2013 , 81, 694-5	6.5	2
124	Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. <i>Neurology</i> , 2013 , 80, 176-80	6.5	150
123	Cognitive impairment and PD patients' capacity to consent to research. <i>Neurology</i> , 2013 , 81, 801-7	6.5	53
122	Is depression in Parkinson's disease (PD) a specific entity?. <i>Journal of Affective Disorders</i> , 2012 , 139, 103-11	6.5	29
121	Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale. <i>Movement Disorders</i> , 2012 , 27, 242-7	7	202
120	Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. <i>Movement Disorders</i> , 2012 , 27, 349-56	7	1373
119	Genetic influences on cognitive decline in Parkinson's disease. <i>Movement Disorders</i> , 2012 , 27, 512-8	7	100
118	Citalopram for agitation in Alzheimer's disease: design and methods. <i>Alzheimer's and Dementia</i> , 2012 , 8, 121-30	1.2	42
117	Cognitive outcomes after sertraline treatment in patients with depression of Alzheimer disease. <i>American Journal of Geriatric Psychiatry</i> , 2012 , 20, 1036-44	6.5	33

116	Medication management and neuropsychological performance in Parkinson's disease. <i>Clinical Neuropsychologist</i> , 2012 , 26, 45-58	4.4	30
115	Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. <i>Brain</i> , 2012 , 135, 170-80	11.2	122
114	Psychosis in Parkinson's disease without dementia: common and comorbid with other non-motor symptoms. <i>Movement Disorders</i> , 2012 , 27, 858-63	7	85
113	Anxiety Syndromes and Panic Attacks 2011 , 193-201		1
112	Sertraline for the treatment of depression in Alzheimer disease: genetic influences. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2011 , 24, 222-8	3.8	10
111	Patient versus informant reporting of ICD symptoms in Parkinson's disease using the QUIP: validity and variability. <i>Parkinsonism and Related Disorders</i> , 2011 , 17, 153-5	3.6	52
110	Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. <i>Archives of Neurology</i> , 2011 , 68, 899-904		85
109	Parkinson's disease: the quintessential neuropsychiatric disorder. <i>Movement Disorders</i> , 2011 , 26, 1022-31		277
108	Both the body and brain benefit from exercise: potential win-win for Parkinson's disease patients. <i>Movement Disorders</i> , 2011 , 26, 607	7	3
107	Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 2051-7	7	57
106	MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. <i>Movement Disorders</i> , 2011 , 26, 1814-24	7	527
105	The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26 Suppl 3, S42-80	7	599
104	Cognitive impairment in nondemented Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 2483-95	7	95
103	Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. <i>Annals of Neurology</i> , 2011 , 69, 655-63	9.4	103
102	Impulse control disorders in Parkinson disease: a multicenter case-control study. <i>Annals of Neurology</i> , 2011 , 69, 986-96	9.4	296
101	Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study # 2 (DIADS-2)? <i>International Journal of Geriatric Psychiatry</i> , 2011 , 26, 573-83	3.9	41
100	Neurodegeneration across stages of cognitive decline in Parkinson disease. <i>Archives of Neurology</i> , 2011 , 68, 1562-8		149
99	Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2011 , 26, 443-9	2.5	32

98	Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours. <i>International Journal of Neuroscience</i> , 2011 , 121, 472-6	2	5
97	Case for and against specificity of depression in Alzheimer's disease. <i>Psychiatry and Clinical Neurosciences</i> , 2010 , 64, 358-66	6.2	14
96	Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. <i>Neurology</i> , 2010 , 75, 448-55	6.5	176
95	Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. <i>Neurology</i> , 2010 , 75, 478; author reply 478-9	6.5	32
94	Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. <i>Neurology</i> , 2010 , 75, 1062-9	6.5	522
93	Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. <i>Archives of Neurology</i> , 2010 , 67, 589-95		988
92	CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. <i>Neurology</i> , 2010 , 75, 1055-61	6.5	249
91	Psychiatric Issues in Parkinson's Disease. <i>Blue Books of Neurology</i> , 2010 , 34, 213-228		3
90	Sertraline for the treatment of depression in Alzheimer disease. <i>American Journal of Geriatric Psychiatry</i> , 2010 , 18, 136-45	6.5	154
89	Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. <i>American Journal of Geriatric Psychiatry</i> , 2010 , 18, 332-40	6.5	114
88	Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , 2010 , 9, 573-80	24.1	382
87	Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. <i>Annals of Neurology</i> , 2010 , 68, 963-8	9.4	105
86	Association between cognition and function in patients with Parkinson disease with and without dementia. <i>Movement Disorders</i> , 2010 , 25, 1170-6	7	109
85	Decreased ventral striatal activity with impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 1660-9	7	117
84	Treatment of early Parkinson's disease. Part 1. <i>European Neurology</i> , 2009 , 61, 193-205	2.1	10
83	Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. <i>Neurology</i> , 2009 , 73, 1738-45	6.5	687
82	Treatment of early Parkinson's disease. Part 2. <i>European Neurology</i> , 2009 , 61, 206-15	2.1	10
81	Impulsive and compulsive behaviors in Parkinson's disease. <i>Movement Disorders</i> , 2009 , 24, 1561-70	7	163

80	Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. <i>Movement Disorders</i> , 2009 , 24, 1461-7	7	294
79	The course of depressive symptoms in early Parkinson's disease. <i>Movement Disorders</i> , 2009 , 24, 1306-11	7	34
78	Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score. <i>Journal of the American Geriatrics Society</i> , 2009 , 57, 304-8	5.6	238
77	Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores. <i>Parkinsonism and Related Disorders</i> , 2009 , 15, 226-31	3.6	138
76	Involuntary emotional expression disorder (IEED) in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009 , 15, 511-5	3.6	16
75	Pattern of Depressive Symptoms in Parkinson's Disease. <i>Psychosomatics</i> , 2009 , 50, 448-454	2.6	19
74	Impulse control disorders in Parkinson's disease: prevalence and possible risk factors. <i>Parkinsonism and Related Disorders</i> , 2009 , 15 Suppl 3, S110-3	3.6	66
73	Use of latent variable modeling to delineate psychiatric and cognitive profiles in Parkinson disease. <i>American Journal of Geriatric Psychiatry</i> , 2009 , 17, 986-95	6.5	19
72	Frequency and correlates of involuntary emotional expression disorder in Parkinson's disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2009 , 21, 406-12	2.7	17
71	Pattern of depressive symptoms in Parkinson's disease. <i>Psychosomatics</i> , 2009 , 50, 448-54	2.6	6
70	Dopamine and impulse control disorders in Parkinson's disease. <i>Annals of Neurology</i> , 2008 , 64 Suppl 2, S93-100	9.4	92
69	Attitudes regarding the etiology and treatment of depression in Parkinson's disease: a qualitative study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2008 , 21, 123-32	3.8	39
68	Drs. Weintraub and Hurtig Reply. <i>American Journal of Psychiatry</i> , 2008 , 165, 261	11.9	
67	Long-term follow-up of impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2008 , 23, 75-80	7	185
66	Suicidal and death ideation in Parkinson's disease. <i>Movement Disorders</i> , 2008 , 23, 1573-9	7	93
65	Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. <i>Movement Disorders</i> , 2008 , 23, 2004-14	7	242
64	Anxiety rating scales in Parkinson's disease: critique and recommendations. <i>Movement Disorders</i> , 2008 , 23, 2015-25	7	182
63	Diagnosis and management of Parkinson's disease dementia. <i>International Journal of Clinical Practice</i> , 2008 , 62, 1581-7	2.9	61

62	Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment. <i>American Journal of Managed Care</i> , 2008 , 14, S40-8	2.1	123
61	Disorders of mood and affect in Parkinson's disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2007 , 83, 421-33	3	3
60	Drug Insight: impulse control disorders and dopamine therapies in Parkinson's disease. <i>Nature Clinical Practice Neurology</i> , 2007 , 3, 664-72		68
59	Depression in veterans with Parkinson's disease: frequency, co-morbidity, and healthcare utilization. <i>International Journal of Geriatric Psychiatry</i> , 2007 , 22, 543-8	3.9	22
58	Differences in depression symptoms in patients with Alzheimer's and Parkinson's diseases: evidence from the 15-item Geriatric Depression Scale (GDS-15). <i>International Journal of Geriatric Psychiatry</i> , 2007 , 22, 1025-30	3.9	15
57	Depression rating scales in Parkinson's disease: critique and recommendations. <i>Movement Disorders</i> , 2007 , 22, 1077-92	7	490
56	Effect of age on geriatric depression scale performance in Parkinson's disease. <i>Movement Disorders</i> , 2007 , 22, 1331-5	7	56
55	Intervening in the neuropsychiatric features of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2007 , 7, 699-710	4.3	5
54	Comparison and predictors of rash associated with 15 antiepileptic drugs. <i>Neurology</i> , 2007 , 68, 1701-9	6.5	193
53	The impact of depressive symptoms in early Parkinson disease. <i>Neurology</i> , 2007 , 69, 342-7	6.5	230
52	Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies. <i>American Journal of Psychiatry</i> , 2007 , 164, 1491-8	11.9	83
51	Antidepressant treatment of veterans with Parkinson's disease and depression: analysis of a national sample. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2007 , 20, 161-5	3.8	38
50	Phenylthiocarbamide (PTC) perception in Parkinson disease. <i>Cognitive and Behavioral Neurology</i> , 2007 , 20, 145-8	1.6	15
49	Impulse control disorders in Parkinson's disease. <i>Current Neurology and Neuroscience Reports</i> , 2006 , 6, 302-6	6.6	56
48	Association of dopamine agonist use with impulse control disorders in Parkinson disease. <i>Archives of Neurology</i> , 2006 , 63, 969-73		511
47	Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. <i>New England Journal of Medicine</i> , 2006 , 355, 1525-38	59.2	875
46	Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease. <i>American Journal of Geriatric Psychiatry</i> , 2006 , 14, 169-75	6.5	166
45	Daily affect in Parkinson disease is responsive to life events and motor symptoms. <i>American Journal of Geriatric Psychiatry</i> , 2006 , 14, 161-8	6.5	14

44	Frequency and correlates of co-morbid psychosis and depression in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2006 , 12, 427-31	3.6	30
43	Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2006 , 18, 377-83	2.7	24
42	Defining and diagnosing involuntary emotional expression disorder. <i>CNS Spectrums</i> , 2006 , 11, 1-7	1.8	152
41	Therapeutic options for emotional lability: current and emerging treatments. <i>American Journal of Geriatric Pharmacotherapy</i> , 2005 , 3 Suppl A, 12-5; quiz 16-7		2
40	[99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease. <i>Neurology</i> , 2005 , 64, 1716-20	6.5	130
39	Psychiatric Complications in Parkinson Disease. <i>American Journal of Geriatric Psychiatry</i> , 2005 , 13, 844-851	5.5	86
38	Pharmacologic interventions for psychosis and agitation in neurodegenerative diseases: evidence about efficacy and safety. <i>Psychiatric Clinics of North America</i> , 2005 , 28, 941-83, ix-x	3.1	8
37	Electroconvulsive therapy for depression in a Parkinson's disease patient with bilateral subthalamic nucleus deep brain stimulators. <i>Parkinsonism and Related Disorders</i> , 2005 , 11, 403-6	3.6	23
36	Antidepressant studies in Parkinson's disease: a review and meta-analysis. <i>Movement Disorders</i> , 2005 , 20, 1161-9	7	144
35	Dimensions of executive function in Parkinson's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005 , 20, 140-4	2.6	68
34	Psychiatric complications in Parkinson disease. <i>American Journal of Geriatric Psychiatry</i> , 2005 , 13, 844-51	6.5	36
33	Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. <i>Journal of Nuclear Medicine</i> , 2005 , 46, 227-32	8.9	156
32	Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. <i>Journal of the American Geriatrics Society</i> , 2004 , 52, 784-8	5.6	289
31	Diagnosing and Treating Depression in Patients With Parkinson's Disease. <i>Psychiatric Annals</i> , 2004 , 34, 298-304	0.5	2
30	Evidence for impaired encoding and retrieval memory profiles in Parkinson disease. <i>Cognitive and Behavioral Neurology</i> , 2004 , 17, 195-200	1.6	73
29	Pharmacologic management of psychosis in the elderly: a critical review. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2003 , 16, 213-8	3.8	9
28	Recognition and treatment of depression in Parkinson's disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2003 , 16, 178-83	3.8	149
27	Effect of increasing the dose and duration of sertraline trial in the treatment of depressed nursing home residents. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2003 , 16, 109-11	3.8	10

26	Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. <i>Journal of Clinical Psychiatry</i> , 2003 , 64, 875-82	4.6	72
25	Second-generation issues in the management of depression in nursing homes. <i>Journal of the American Geriatrics Society</i> , 2002 , 50, 2100-1; author reply 2101	5.6	7
24	Change in the rate of restraint use and falls on a psychogeriatric inpatient unit: impact of the health care financing administration's new restraint and seclusion standards for hospitals. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2002 , 15, 91-4	3.8	5
23	Delirious mania in the elderly. <i>International Journal of Geriatric Psychiatry</i> , 2001 , 16, 374-7	3.9	11
22	Nortriptyline toxicity secondary to interaction with bupropion sustained-release. <i>Depression and Anxiety</i> , 2001 , 13, 50-2	8.4	16
21	Nortriptyline in geriatric depression resistant to serotonin reuptake inhibitors: case series. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2001 , 14, 28-32	3.8	5
20	Psychiatric assessment of a nursing home population using audiovisual telecommunication. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2001 , 14, 63-5	3.8	34
19	Amphetamine positive toxicology screen secondary to bupropion. <i>Depression and Anxiety</i> , 2000 , 12, 53-48.4		21
18	Clinical and demographic changes over ten years on a psychogeriatric inpatient unit. <i>Annals of Clinical Psychiatry</i> , 2000 , 12, 227-31	1.4	
17	Residents in Personal Psychotherapy. <i>Academic Psychiatry</i> , 1999 , 23, 14-19	1.1	9
16	Electroconvulsive Therapy for Epilepsy and Major Depression. <i>American Journal of Geriatric Psychiatry</i> , 1998 , 6, 180-183	6.5	21
15	Lessons and challenges of trials for cognitive and behavioral complications of Parkinson's disease325-336		
14	The boundaries of Parkinson's disease dementia and dementia with Lewy bodies40-52		
13	Cognitive assessment in Parkinson's disease53-64		
12	Clinical assessment: mood and motivation65-72		
11	Diagnosis and biomarkers: CSF97-108		
10	Apathy131-139		
9	Impulse control disorders and related behaviors140-152		2

8 Psychosis153-162

7 Early cognitive impairment163-176

6 Parkinson’s disease dementia177-191

5 Sleep disturbances192-210

4 The impact of neuropsychiatric symptoms on quality of life in Parkinson’s disease255-260

3 Neuropsychiatric aspects of the on/off phenomenon275-284

2 An International Multicenter Analysis of Brain Structure across Clinical Stages of Parkinson’s Disease: The ENIGMA-Parkinson’s Study 1

1 Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease Progression 2